CSL Shares Hit Multi-Year Low as Pentagon Scraps Flu Vaccine Mandate
Synopsis
CSL, Australia’s premier biotech firm, saw its shares plummet to a nearly 10-year low on April 23, 2026, following a shock decision by the U.S. Department of Defense to make flu vaccines optional. The policy shift directly threatens the revenue of CSL's Seqirus division, which views the U.S. military as a critical institutional customer. Already struggling with high plasma collection costs and a 25% yearly stock decline, the company now faces an uphill battle to restore investor confidence. As the firm undergoes a massive $700 million restructuring, analysts warn that the loss of guaranteed vaccine demand may further delay CSL's recovery.
Australian biotech giant CSL has seen its shares plunge to their lowest level since 2017. This latest drop comes as the U.S. The Department of Defense makes a significant policy move away from mandatory flu vaccinations for military personnel, endangering one of its vaccine unit’s more lucrative revenue sources.
Key Highlights
- CSL shares dropped to a low of around $128.67, the lowest price since August 2017
- The U.S. The Pentagon abandoned its compulsory flu vaccine policy.
- The U.S. provides CSL Seqirus, the company’s vaccine business, with its largest market.
- Generally, the stock has lost 25% over the past year amid more extensive earnings problems.
- Investors have worries about expensive production and gradual rebound in the plasma segment.
Demand For Vaccine Takes A Hit After Pentagon Policy Shift
CSL shares were down further following the announcement from the U.S. military that annual vaccination for influenza was no longer a requirement for service personnel. Pete Hegseth, secretary of war, stamps the memorandum removing mandatory shot requirements for all active and reserve troops effective immediately. That is an abrupt turnaround from a long career. The U.S. military is a large institutional purchaser of vaccines and analysts cautioned this would reduce CSL’s Sequirus division, which earned about $2.17 billion (A$3.35 billion) in fiscal 2025 revenue, guaranteed demand significantly.
Biotech Giant still faces Compounding Problems
The announcement came when CSL’s position was already weak, making this news the most important reason for the stock’s recent sink. It has been struggling with long-term depressed earnings owing to elevated expense levels in its primary plasma-derived therapy business. Plasma collection was considerably impacted by the pandemic, and CSL spent $1.5 billion expanding its manufacturing site in Illinois during that time to recover from that impact, but investors have not seen as fast a return as they might have liked. The increased pressure on CSL’s important vaccine segment, made up of some of the company’s most reliably profitable safety nets, has many thinking that the growth path for the company is well and truly in peril.
CSL saw its underlying net profit (NPATA) drop 7% in the first half of the 2026 fiscal year. Market strategists said the Pentagon signalled it was the straw that broke the camel’s back and placed further pricing pressure on top of a muted outlook for the U.S. immunoglobulin market and intensifying competition from new drug discovery tools using AI. The valuation of CSL, which used to be the most expensive stock on the Australian market, is now close to 25 times forward earnings and with that has whittled away at the quality premium it once commanded relative to peers.
Expert Take and Future Strategy
GlobalXETFs and Vantage Markets investment strategists say that CSL now has a confidence gap. Even as the company undergoes its biggest restructuring, $700 million in costs and an aim to save $550 million annually by 2028, the market has clearly not found a floor for the share price. Management has left its full year revenue growth guidance unchanged at 2-3%, but the path of recovering underpinning by mandatory vaccine sales and realization of higher end $1.5 billion plasma investments will be crucial in delivering better margins by 2027, sustaining the road to recovery.
FAQs
- The U.S. military changed its policy on mandatory flu shots, but why?
The Pentagon said the requirement was wide ranging and service members should be able to make an informed health choice.
- What portion of CSL’s business is comprised by flu vaccines?
Seqirus (vaccines) is 14% of CSL’s total global sales.
- What is the plasma business and why has it been struggling?
They harvest human plasma from around 30 CSL centers to develop therapies for rare diseases. The expense of compensating donors and handling the blood has spiked, eating into the bank’s profit.
- When will the newly appointed CEO start?
The current CEO is Dr. Paul McKenzie however, the board had been recently switched and Gordon Naylor, a previous CEO of its vaccine division became chairman.
Follow Inspirepreneur Magazine for daily global business news.
At Inspirepreneurs Magazine, covering entrepreneurship, business failures, and the human stories behind the world's most ambitious founders. She writes at the intersection of strategy and storytelling.
